Remoxipride
Remoxipride (pronunciation: /rɛˈmɒksɪpraɪd/) is an atypical antipsychotic and dopamine antagonist primarily used in the treatment of schizophrenia. It was developed by AstraZeneca (then Astra AB) and introduced in the 1980s.
Etymology
The term "Remoxipride" is derived from its chemical name, 3-bromo-N-((1-ethylpyrrolidin-2-yl)methyl)-2,6-dimethoxybenzamide.
Pharmacology
Remoxipride acts as a selective D2 and D3 receptor antagonist in the brain, which is believed to reduce the symptoms of schizophrenia. It has a high affinity for these receptors and is considered atypical due to its minimal effects on the muscarinic acetylcholine receptors and serotonin receptors.
Clinical Use
Remoxipride is primarily used in the treatment of schizophrenia. It has been found to be effective in reducing both positive and negative symptoms of the disorder. However, its use has been limited due to the risk of agranulocytosis, a potentially fatal decrease in the number of white blood cells.
Side Effects
Common side effects of Remoxipride include drowsiness, dizziness, and dry mouth. More serious side effects may include agranulocytosis, neuroleptic malignant syndrome, and tardive dyskinesia.
Related Terms
- Atypical antipsychotic
- Dopamine antagonist
- Schizophrenia
- Agranulocytosis
- Neuroleptic malignant syndrome
- Tardive dyskinesia
External links
- Medical encyclopedia article on Remoxipride
- Wikipedia's article - Remoxipride
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski